Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
作者信息
Grasso Catherine S, Tsoi Jennifer, Onyshchenko Mykola, Abril-Rodriguez Gabriel, Ross-Macdonald Petra, Wind-Rotolo Megan, Champhekar Ameya, Medina Egmidio, Torrejon Davis Y, Shin Daniel Sanghoon, Tran Phuong, Kim Yeon Joo, Puig-Saus Cristina, Campbell Katie, Vega-Crespo Agustin, Quist Michael, Martignier Christophe, Luke Jason J, Wolchok Jedd D, Johnson Douglas B, Chmielowski Bartosz, Hodi F Stephen, Bhatia Shailender, Sharfman William, Urba Walter J, Slingluff Craig L, Diab Adi, Haanen John B A G, Algarra Salvador Martin, Pardoll Drew M, Anagnostou Valsamo, Topalian Suzanne L, Velculescu Victor E, Speiser Daniel E, Kalbasi Anusha, Ribas Antoni
出版信息
Cancer Cell. 2021 Jan 11;39(1):122. doi: 10.1016/j.ccell.2020.11.015. Epub 2020 Dec 10.
Abstract
摘要
相似文献
1
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.保守的干扰素-γ信号通路驱动黑色素瘤对免疫检查点阻断疗法的临床反应。
Cancer Cell. 2021 Jan 11;39(1):122. doi: 10.1016/j.ccell.2020.11.015. Epub 2020 Dec 10.
2
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
3
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade.干扰素协调适应性和先天免疫反应对癌症免疫检查点阻断的拮抗作用。
Cell. 2019 Aug 8;178(4):933-948.e14. doi: 10.1016/j.cell.2019.07.019.
4
Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.编码干扰素信号传导和抗原呈递的基因中的突变模式：一项泛癌研究及其对免疫检查点抑制剂使用的启示
Genes Chromosomes Cancer. 2017 Aug;56(8):651-659. doi: 10.1002/gcc.22468. Epub 2017 May 31.
5
Immune checkpoint blockade and interferon-α in melanoma.黑色素瘤中的免疫检查点阻断与干扰素-α
Semin Oncol. 2015 Jun;42(3):436-47. doi: 10.1053/j.seminoncol.2015.02.012. Epub 2015 Feb 14.
6
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.在黑色素瘤的靶向治疗与免疫检查点阻断治疗进展时，观察到了不同的临床模式和免疫浸润情况。
Oncoimmunology. 2016 Feb 2;5(3):e1136044. doi: 10.1080/2162402X.2015.1136044. eCollection 2016 Mar.
7
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.联合中枢耐受和外周检查点阻断可释放抗黑色素瘤免疫。
JCI Insight. 2017 Sep 21;2(18). doi: 10.1172/jci.insight.93265.
8
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.对纵向肿瘤样本中的免疫特征进行分析，有助于深入了解免疫检查点阻断反应的生物标志物和耐药机制。
Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.
9
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.CTLA-4 和 PD-1/PD-L1 阻断：黑色素瘤患者具有持久临床获益的新免疫治疗方式。
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
10
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.联合阻断 IL6 和 PD-1/PD-L1 信号通路可消除肿瘤微环境中它们免疫抑制作用的相互调节。
Cancer Res. 2018 Sep 1;78(17):5011-5022. doi: 10.1158/0008-5472.CAN-18-0118. Epub 2018 Jul 2.
引用本文的文献
1
LRP2 Expression in Melanoma Is Associated With a Transitory Cell State, Increased T Cell Infiltration, and Is Upregulated by IFNy Signaling.LRP2在黑色素瘤中的表达与一种短暂的细胞状态、T细胞浸润增加相关，且受IFNy信号上调。
Pigment Cell Melanoma Res. 2025 Sep;38(5):e70053. doi: 10.1111/pcmr.70053.
2
Monitoring T-Cell Activation in the Tumor Microenvironment by PET Imaging of the Chemokine CXCL9.通过趋化因子CXCL9的PET成像监测肿瘤微环境中的T细胞活化
J Nucl Med. 2025 Sep 2;66(9):1372-1377. doi: 10.2967/jnumed.125.269795.
3
Transitory Schwann Cell Precursor and hybrid states underpin melanoma therapy resistance and metastasis.短暂性施万细胞前体和混合状态是黑色素瘤治疗耐药性和转移的基础。
bioRxiv. 2025 Jul 23:2022.10.14.512297. doi: 10.1101/2022.10.14.512297.
4
Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.肿瘤细胞内在的Decr2调节铁死亡和免疫治疗疗效。
Cancer Immunol Res. 2025 Aug 1;13(8):1284-1302. doi: 10.1158/2326-6066.CIR-24-0519.
5
Programmed Death-1 Ligand 1 Domain Organization, Signaling Motifs, and Interactors in Cancer Immunotherapy.癌症免疫治疗中的程序性死亡-1配体1结构域组织、信号基序及相互作用分子
Cancers (Basel). 2025 May 12;17(10):1635. doi: 10.3390/cancers17101635.
6
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors.γ干扰素在黑色素瘤患者对免疫检查点抑制剂免疫治疗反应中的双重作用
Mol Cancer. 2025 Mar 20;24(1):89. doi: 10.1186/s12943-025-02294-x.
7
Crosstalk Between nNOS/NO and COX-2 Enhances Interferon-Gamma-Stimulated Melanoma Progression.nNOS/NO与COX-2之间的相互作用促进干扰素-γ刺激的黑色素瘤进展。
Cancers (Basel). 2025 Jan 31;17(3):477. doi: 10.3390/cancers17030477.
8
Predicting Survival Rates in Brain Metastases Patients from Non-Small Cell Lung Cancer Using Radiomic Signatures Associated with Tumor Immune Heterogeneity.利用与肿瘤免疫异质性相关的放射组学特征预测非小细胞肺癌脑转移患者的生存率
Adv Sci (Weinh). 2025 Mar;12(10):e2412590. doi: 10.1002/advs.202412590. Epub 2025 Jan 22.
9
Cancer immune evasion, immunoediting and intratumour heterogeneity.癌症免疫逃逸、免疫编辑与肿瘤内异质性。
Nat Rev Immunol. 2025 May;25(5):353-369. doi: 10.1038/s41577-024-01111-8. Epub 2025 Jan 2.
10
Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review.程序性死亡蛋白1（PD-1）抑制剂诱发的序贯性严重免疫相关不良事件：1例病例报告及文献综述
Front Oncol. 2024 Jul 29;14:1391698. doi: 10.3389/fonc.2024.1391698. eCollection 2024.
Zotero 插件